由于过度延长QT间隔而导致不成功的多菲提利德启动相关的危险因素:一项回顾性研究
Johnathon Rast1, Grant Whitebloom1, Omar M Makram1
1Department of Medicine, Medical College of Georgia at Augusta University, Augusta, GA, USA.
The Journal of innovations in cardiac rhythm management
|April 18, 2025
概括
开始服用多菲提利德可以导致过度的QTc延长,特别是在心力衰竭患者中. 这项研究确定了关键的风险因素,包括心脏功能受损,这表明这些患者可能无法耐受药物.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多菲提利德是治疗心房动的第三类抗失律药.
- 过度的QTc延长是一个风险,可能导致torsades de pointes.
- 目前的协议包括在初始多菲提利德剂量期间的住院监测.
研究的目的:
- 为了确定多提利德开始时过度QTc延长的危险因素.
- 调查伴随疾病,心声回声学值和QTc延长之间的关联.
主要方法:
- 单中心回顾性队列研究.
- 在心房动患者中对多菲提利德启动的分析.
- QTc间隔变化与病史和心声回声数据的相关性.
主要成果:
- 心力衰竭史,左心室射出分数减少,左心室终端-透气直径增加,左心房直径增加和右心室缩功能减少是显著的危险因素.
- 由于QTc延长,心力衰竭患者不太可能耐受多费提利德的启动.
结论:
- 特定的患者特征增加了多菲提利德诱导的QTc延长的风险.
- 心力衰竭患者可能比以前认为的对多费提利德的耐受性较低,尽管在开始后证明了它的安全性.
更多相关视频
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
808
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
808
Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
680
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
680
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.0K
Disturbances in Heart Rhythm
710
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
710
Antiepileptic Drugs: Potassium Channel Activators
123
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
123


